Cosmo Pharmaceuticals N.V. (ETR:C43)
Germany
· Delayed Price · Currency is EUR 58.00
+0.50 (0.87%)
Last updated: Mar 27, 2025
Cosmo Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 266.79 | 92.78 | 102.09 | 65.07 | 60.95 | Upgrade
|
| Revenue | 266.79 | 92.78 | 102.09 | 65.07 | 60.95 | Upgrade
|
| Revenue Growth (YoY) | 187.55% | -9.12% | 56.88% | 6.77% | -2.47% | Upgrade
|
| Cost of Revenue | 45.36 | 39.34 | 40.49 | 32.98 | 27.62 | Upgrade
|
| Gross Profit | 221.43 | 53.44 | 61.6 | 32.1 | 33.33 | Upgrade
|
| Selling, General & Admin | 41.53 | 37.99 | 19.98 | 10.52 | 18.68 | Upgrade
|
| Research & Development | 34.68 | 19.25 | 15.46 | 11.29 | 13.6 | Upgrade
|
| Other Operating Expenses | -3.66 | -1.92 | -1.9 | -0.82 | -0.75 | Upgrade
|
| Operating Expenses | 72.55 | 55.32 | 33.54 | 21 | 31.53 | Upgrade
|
| Operating Income | 148.88 | -1.88 | 28.06 | 11.1 | 1.81 | Upgrade
|
| Interest Expense | -0.05 | -8.53 | -9.16 | -8.99 | -8.73 | Upgrade
|
| Interest & Investment Income | 1.67 | 4.07 | 2.94 | 3.06 | 1.75 | Upgrade
|
| Earnings From Equity Investments | - | - | - | 17.75 | -4.94 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.02 | -1.36 | 2.76 | 2.24 | -1.49 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.07 | -0.12 | -0.11 | -0.48 | -0.17 | Upgrade
|
| EBT Excluding Unusual Items | 151.45 | -7.81 | 24.49 | 24.68 | -11.78 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.92 | 1.33 | -0.02 | -0.68 | -0.25 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 4 | Upgrade
|
| Other Unusual Items | - | - | - | - | 1.1 | Upgrade
|
| Pretax Income | 153.37 | -6.49 | 24.47 | 24 | -6.93 | Upgrade
|
| Income Tax Expense | 20.18 | 4.21 | 6.97 | 2.33 | 0.97 | Upgrade
|
| Earnings From Continuing Operations | 133.19 | -10.7 | 17.51 | 21.67 | -7.9 | Upgrade
|
| Minority Interest in Earnings | 0.05 | -0.08 | -0.28 | -0 | - | Upgrade
|
| Net Income | 133.24 | -10.78 | 17.23 | 21.67 | -7.9 | Upgrade
|
| Net Income to Common | 133.24 | -10.78 | 17.23 | 21.67 | -7.9 | Upgrade
|
| Net Income Growth | - | - | -20.52% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 16 | 16 | 16 | 17 | 14 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 16 | 16 | 17 | 14 | Upgrade
|
| Shares Change (YoY) | 1.94% | -1.95% | -2.83% | 16.81% | -1.11% | Upgrade
|
| EPS (Basic) | 8.14 | -0.67 | 1.05 | 1.29 | -0.55 | Upgrade
|
| EPS (Diluted) | 8.12 | -0.67 | 1.05 | 1.28 | -0.55 | Upgrade
|
| EPS Growth | - | - | -18.20% | - | - | Upgrade
|
| Free Cash Flow | 157.86 | 19.36 | 28.71 | 7.12 | 8.87 | Upgrade
|
| Free Cash Flow Per Share | 9.62 | 1.20 | 1.75 | 0.42 | 0.61 | Upgrade
|
| Dividend Per Share | 2.050 | 2.000 | 1.050 | 0.950 | - | Upgrade
|
| Dividend Growth | 2.50% | 90.48% | 10.53% | - | - | Upgrade
|
| Gross Margin | 83.00% | 57.60% | 60.34% | 49.32% | 54.69% | Upgrade
|
| Operating Margin | 55.81% | -2.02% | 27.48% | 17.06% | 2.96% | Upgrade
|
| Profit Margin | 49.94% | -11.62% | 16.87% | 33.30% | -12.96% | Upgrade
|
| Free Cash Flow Margin | 59.17% | 20.87% | 28.12% | 10.95% | 14.54% | Upgrade
|
| EBITDA | 160.47 | 9.27 | 41.17 | 17.81 | 6.06 | Upgrade
|
| EBITDA Margin | 60.15% | 9.99% | 40.33% | 27.37% | 9.94% | Upgrade
|
| D&A For EBITDA | 11.59 | 11.14 | 13.11 | 6.71 | 4.25 | Upgrade
|
| EBIT | 148.88 | -1.88 | 28.06 | 11.1 | 1.81 | Upgrade
|
| EBIT Margin | 55.81% | -2.02% | 27.48% | 17.06% | 2.96% | Upgrade
|
| Effective Tax Rate | 13.15% | - | 28.47% | 9.71% | - | Upgrade
|
Updated Jul 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.